Phases IIa trial reports that tildrakizumab treatment did not improve ASAS20 response rate in ankylosing spondylitis patients
An anti-interleukin-23p19 monoclonal antibody known as tildrakizumab has received approval for treating moderate to severe plaque psoriasis. However, a recent study published in the Journal …